Literature DB >> 25374430

Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical Trials.

A D Hartkopf1, T Fehm1, M Wallwiener2, U Lauer3.   

Abstract

Oncolytic viruses are replication competent "live" viruses. They infect tumor cells, replicate highly selective inside and thereby destroy them. Because of the enormous advances in the field of genetic engineering and biotechnology during the last decade, virotherapy is increasingly used within clinical trials and proved to be safe and effective. In particular, treatment of ovarian cancer patients is one main focus of research. On the one hand, this is due to the poor prognosis of this dismal entity, resulting in the urgent need for novel therapeutics. On the other hand, as ovarian cancer typically spreads within the peritoneal cavity, intraperitoneal administration of oncolytic viruses is feasible. This paper provides an overview of promising results from clinical trials to treat ovarian cancer patients with oncolytic viruses.

Entities:  

Keywords:  biomarker; breast; cell culture; ovarian cancer

Year:  2012        PMID: 25374430      PMCID: PMC4215573          DOI: 10.1055/s-0031-1298281

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  47 in total

Review 1.  Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

Authors:  D Kirn; R L Martuza; J Zwiebel
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

2.  Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.

Authors:  Gerd J Bauerschmitz; John T Lam; Anna Kanerva; Kaori Suzuki; Dirk M Nettelbeck; Igor Dmitriev; Victor Krasnykh; Galina V Mikheeva; Mack N Barnes; Ronald D Alvarez; Peter Dall; Ramon Alemany; David T Curiel; Akseli Hemminki
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

3.  Oncolytic reovirus against ovarian and colon cancer.

Authors:  Kensuke Hirasawa; Sandra G Nishikawa; Kara L Norman; Tommy Alain; Anna Kossakowska; Patrick W K Lee
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

4.  Use of vaccinia virus in the treatment of metastatic malignant melanoma.

Authors:  I Hunter-Craig; K A Newton; G Westbury; B W Lacey
Journal:  Br Med J       Date:  1970-05-30

5.  Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer.

Authors:  L G Gomella; M J Mastrangelo; P A McCue; J R Maguire HC; S G Mulholland; E C Lattime
Journal:  J Urol       Date:  2001-10       Impact factor: 7.450

6.  Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.

Authors:  Giulia Fulci; Laura Breymann; Davide Gianni; Kazuhiko Kurozomi; Sarah S Rhee; Jianhua Yu; Balveen Kaur; David N Louis; Ralph Weissleder; Michael A Caligiuri; E Antonio Chiocca
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

7.  The human CD46 molecule is a receptor for measles virus (Edmonston strain).

Authors:  R E Dörig; A Marcil; A Chopra; C D Richardson
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

Review 8.  Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.

Authors:  Candice Willmon; Kevin Harrington; Timothy Kottke; Robin Prestwich; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

9.  Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases.

Authors:  S Arakawa; G Hamami; K Umezu; S Kamidono; J Ishigami; S Arakawa
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

10.  Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene.

Authors:  S Chalikonda; M H Kivlen; M E O'Malley; X D Eric Dong; J A McCart; M C Gorry; X-Y Yin; C K Brown; H J Zeh; Z S Guo; D L Bartlett
Journal:  Cancer Gene Ther       Date:  2007-12-14       Impact factor: 5.987

View more
  9 in total

1.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

2.  Endometrial Cancer: Comparison of Patients with Synchronous Primary Carcinoma of the Endometrium and Ovary vs. Endometrial Carcinoma with Ovarian Metastases.

Authors:  I Juhasz-Böss; T Fehm; S Becker; R Rothmund; B Krämer; A Staebler; D Wallwiener; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-08-16       Impact factor: 2.915

3.  Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis.

Authors:  Nina Marí Gual Pimenta de Queiroz; Tianli Xia; Hiroyasu Konno; Glen N Barber
Journal:  Mol Cancer Res       Date:  2018-12-26       Impact factor: 5.852

4.  Small Cell Ovarian Carcinomas - Characterisation of Two Rare Tumor Entities.

Authors:  K Münstedt; R Estel; T Dreyer; A Kurata; A Benz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-07       Impact factor: 2.915

Review 5.  Oncolytic myxoma virus: the path to clinic.

Authors:  Winnie M Chan; Masmudur M Rahman; Grant McFadden
Journal:  Vaccine       Date:  2013-05-29       Impact factor: 3.641

Review 6.  Concise Review: Neural Stem Cell-Mediated Targeted Cancer Therapies.

Authors:  Rachael Mooney; Mohamed Hammad; Jennifer Batalla-Covello; Asma Abdul Majid; Karen S Aboody
Journal:  Stem Cells Transl Med       Date:  2018-08-21       Impact factor: 6.940

Review 7.  Ovarian cancer: Current status and strategies for improving therapeutic outcomes.

Authors:  Ashwin Chandra; Cima Pius; Madiha Nabeel; Maya Nair; Jamboor K Vishwanatha; Sarfraz Ahmad; Riyaz Basha
Journal:  Cancer Med       Date:  2019-09-27       Impact factor: 4.452

Review 8.  Clinical Trials of Oncolytic Viruses in Breast Cancer.

Authors:  Mary E Carter; André Koch; Ulrich M Lauer; Andreas D Hartkopf
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

Review 9.  Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics.

Authors:  Curtis W McCloskey; Galaxia M Rodriguez; Kristianne J C Galpin; Barbara C Vanderhyden
Journal:  Cancers (Basel)       Date:  2018-07-26       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.